Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 25,000 Shares of Company Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin McCulloch sold 25,000 shares of the firm’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $12.49, for a total transaction of $312,250.00. Following the completion of the transaction, the insider directly owned 1,559,208 shares in the company, valued at approximately $19,474,507.92. The trade was a 1.58% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Monday, November 2nd, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $10.23, for a total transaction of $153,450.00.
• On Thursday, October 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $9.41, for a total value of $141,150.00.
• On Monday, September 28th, Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $10.00, for a total value of $250,000.00.
• On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.49, for a total value of $127,350.00.

Xeris Biopharma Stock Up 16.2%

Xeris Biopharma stock traded up $2.12 during trading hours on Friday, hitting $15.20. The stock had a trading volume of 7,890,466 shares, compared to its average volume of 2,106,974. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. The stock’s 50-day moving average price is $9.49 and its 200-day moving average price is $7.58. Xeris Biopharma Holdings, Inc. has a 12-month low of $5.25 and a 12-month high of $15.21. The stock has a market capitalization of $2.77 billion, a P/E ratio of -138.18 and a beta of 0.61.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $107.23 million for the quarter, compared to the consensus estimate of $101.68 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. Equities research analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Leerink Partners lifted their target price on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Oppenheimer reiterated an “outperform” rating and issued a $21.00 price objective (up from $18.00) on shares of Xeris Biopharma in a research note on Friday. Barclays raised their target price on shares of Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, October 6th. Finally, Piper Sandler reiterated a “neutral” rating and set a $12.00 price objective (up from $8.00) on shares of Xeris Biopharma in a research report on Friday. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.20.

More Xeris Biopharma News

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Quarterly results beat estimates: Xeris reported Q3 2026 earnings of $0.06 per share versus consensus of $0.03, and revenue of $107.23 million versus expectations of $101.68 million. Xeris Q3 2026 results
• Positive Sentiment: More optimistic Recorlev outlook: CEO John Shannon reportedly expects Recorlev to approach $1 billion in annual sales three to four years earlier than previously anticipated, a potential growth catalyst. Reacorlev sales outlook
• Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed Outperform and lifted its target to $21 from $18; HC Wainwright raised its target to $18 from $10 and assigned a Buy rating. Read More. · Read More.
• Neutral Sentiment: Xeris updated its FY 2030 earnings guidance, but the provided report does not include the revised figures. Several insiders also reported sales made under pre-arranged trading plans; these transactions may be less informative than discretionary sales. Read More.
• Negative Sentiment: Piper Sandler maintained a Neutral rating but raised its target to $12 from $8, still below the approximately $14.92 share price cited in the report, signaling valuation concerns despite the target increase. Read More.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in XERS. KBC Group NV bought a new stake in shares of Xeris Biopharma during the 1st quarter valued at $27,000. GK Wealth Management LLC acquired a new stake in Xeris Biopharma in the 3rd quarter valued at approximately $32,000. Allworth Financial LP bought a new position in Xeris Biopharma in the second quarter valued at $34,000. State of Wyoming acquired a new position in shares of Xeris Biopharma during the 2nd quarter worth approximately $52,000. Finally, William Mack & Associates Inc. acquired a new position in shares of Xeris Biopharma during the 3rd quarter worth about $53,000. 42.75% of the stock is owned by institutional investors and hedge funds.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.